

# Katerina Chatzidionysiou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3673616/publications.pdf>

Version: 2024-02-01

61  
papers

5,869  
citations

331259

21  
h-index

138251

58  
g-index

63  
all docs

63  
docs citations

63  
times ranked

6627  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
2	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. <i>Lancet, The</i> , 2009, 374, 459-466.	6.3	278
3	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1101-1136.	0.5	277
4	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1113-1136.	0.5	195
5	Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. <i>Lancet, The</i> , 2012, 379, 1712-1720.	6.3	192
6	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1575-1580.	0.5	188
7	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, 251.	1.6	177
8	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107.	0.5	131
9	Delays in assessment of patients with rheumatoid arthritis: variations across Europe. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1822-1825.	0.5	112
10	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1086-1093.	0.5	79
11	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 374-377.	0.5	64
12	Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2017, 4, e000192.	1.1	61
13	Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 890-896.	0.5	56
14	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1336-1342.	0.5	55
15	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.5	47
16	Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 190-195.	0.6	41
17	A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. <i>RMD Open</i> , 2016, 2, e000133.	1.8	40
18	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	1.6	37

#	ARTICLE	IF	CITATIONS
19	Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. <i>RMD Open</i> , 2019, 5, e000993.	1.8	29
20	Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 2170-2176.	0.9	26
21	Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097697.	1.2	26
22	Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 431-437.	0.6	22
23	Biological treatment in ankylosing spondylitis in the Nordic countries during 2010â€“2016: a collaboration between five biological registries. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 465-474.	0.6	22
24	Protective Effect of the <i>HIF-1A</i> Pro582Ser Polymorphism on Severe Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-8.	1.0	22
25	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. <i>RMD Open</i> , 2018, 4, e000655.	1.8	21
26	Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 304-307.	0.5	21
27	When to initiate and discontinue biologic treatments for rheumatoid arthritis?. <i>Journal of Internal Medicine</i> , 2011, 269, 614-625.	2.7	20
28	Rituximab done: whatâ€™s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 230-236.	0.9	20
29	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 157-168.	1.4	19
30	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017, 44, 162-169.	1.0	17
31	Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. <i>Rheumatology</i> , 2022, 61, 3952-3962.	0.9	17
32	Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e163-e173.	2.2	16
33	Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001278.	1.8	16
34	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitorsâ€”is it time for a paradigm shift?. <i>Clinical Rheumatology</i> , 2021, 40, 1687-1695.	1.0	15
35	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. <i>RMD Open</i> , 2016, 2, e000323.	1.8	13
36	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018, 5, e000287.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , 2021, 7, e001987.	1.8	13
38	Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?. <i>Clinical Rheumatology</i> , 2020, 39, 957-961.	1.0	12
39	Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1006-1007.	0.5	9
40	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. <i>RMD Open</i> , 2020, 6, e001363.	1.8	8
41	Triple therapy or etanercept after methotrexate failure in RA?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 510-512.	3.5	7
42	Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2020, 9, 1813.	1.0	7
43	Established rheumatoid arthritis â€“ Redefining the concept. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101476.	1.4	7
44	Comparison of treatment retention of originator <i>vs</i> biosimilar products in clinical rheumatology practice in Sweden. <i>Rheumatology</i> , 2022, 61, 3596-3605.	0.9	7
45	Could severe COVID-19 be considered a complementopathy?. <i>Lupus Science and Medicine</i> , 2020, 7, e000415.	1.1	6
46	Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL. <i>RMD Open</i> , 2021, 7, e001662.	1.8	6
47	Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 131-140.	0.6	5
48	Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 17-23.	0.6	5
49	Effectiveness of a Second Biologic After Failure of a Nonâ€“tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1512-1518.	1.0	5
50	Beyond Methotrexate and Biologics in RA â€“ Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 120.	0.3	5
51	Rheumatic disease and artistic creativity. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 103-109.	0.3	4
52	Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112687.	2.5	3
53	Response to: â€“ Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trialâ€“ comment on: â€“ Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosusâ€“ <sup>TM</sup> by Chatzidionysiou<i>et al</i>>â€“ <sup>TM</sup> by Bettiol<i>et al</i>>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e141-e141.	0.5	2
54	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. <i>Mediterranean Journal of Rheumatology</i> , 2019, 31, 87.	0.3	2

#	ARTICLE	IF	CITATIONS
55	The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. <i>Rheumatology</i> , 2022, 61, 3647-3656.	0.9	2
56	The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 247.	0.3	1
57	Validation of new classification criteria of rheumatoid arthritis in an international multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 841-847.	0.4	1
58	Latest developments in the treatment of rheumatoid arthritis: is there new hope for patients?. <i>Clinical Practice (London, England)</i> , 2013, 10, 233-236.	0.1	0
59	Optimizing biological treatments for rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 64-75.	0.6	0
60	FRIO082â€¦EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND) Tj ETQq0 0 0 rgBT /Overlo BETWEEN FIVE NATIONAL REGISTERS. , 2019, , .		0
61	<i>Mediterranean Journal of Rheumatology</i> March 2020 Highlights. <i>Mediterranean Journal of Rheumatology</i> , 2019, 31, 1.	0.3	0